دورية أكاديمية
أعرض في EDS

Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma.

التفاصيل البيبلوغرافية
العنوان: Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma.
المؤلفون: Lu J; Department of Dermatology and Skin Science, Research Pavilion, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC V5Z IL8, Canada., Cheng Y; Department of Dermatology and Skin Science, Research Pavilion, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC V5Z IL8, Canada., Zhang G; Department of Dermatology and Skin Science, Research Pavilion, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC V5Z IL8, Canada., Tang Y; Department of Dermatology and Skin Science, Research Pavilion, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC V5Z IL8, Canada., Dong Z; Department of Pathophysiology, Basic Medical College, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China., McElwee KJ; Department of Dermatology and Skin Science, Research Pavilion, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC V5Z IL8, Canada., Li G; Department of Dermatology and Skin Science, Research Pavilion, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC V5Z IL8, Canada.
المصدر: Molecular medicine reports [Mol Med Rep] 2015 Aug; Vol. 12 (2), pp. 2668-76. Date of Electronic Publication: 2015 May 07.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-3004 (Electronic) Linking ISSN: 17912997 NLM ISO Abbreviation: Mol Med Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Athens, Greece : D. A. Spandidos
مواضيع طبية MeSH: Melanoma/*diagnosis , Neuropilin-1/*analysis , Skin/*pathology , Skin Neoplasms/*diagnosis, Biomarkers, Tumor/analysis ; Biomarkers, Tumor/biosynthesis ; Disease Progression ; Female ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Male ; Matrix Metalloproteinase 2/analysis ; Melanoma/pathology ; Middle Aged ; Prognosis ; Skin Neoplasms/pathology ; Tissue Array Analysis ; Up-Regulation
مستخلص: Neuropilin 1 (NRP1), a receptor of vascular endothelial growth factor (VEGF), promotes angiogenesis, tumor growth, tumor invasion and metastasis. However, the function of NRP1 in melanoma progression, as well as the effect of NRP1 expression on the prognosis of patients with melanoma remains unknown. In the present study, NRP1 expression was examined in 460 cases of melanocytic lesions (28 common nevi, 51 dysplastic nevi, 250 primary melanoma and 131 metastatic melanoma) at different stages, using a tissue microarray. The correlation of NRP1 expression with melanoma progression, and its prognostic value in patients with melanoma was examined. In addition, the correlation between matrix metalloproteinase 2 (MMP2) and NRP1 expression in patients with melanoma was analyzed. The results demonstrated that NRP1 expression was significantly increased in primary (56%) and metastatic melanoma (62%), compared with common nevi (11%) and dysplastic nevi (24%). Notably, increased NRP1 expression was correlated with a poorer overall, and disease-specific, 10-year survival (P=0.03 and P=0.002, respectively). Multivariate Cox regression analyses indicated that NRP1 is an independent prognostic marker for melanoma. Furthermore, a significant positive correlation between NRP1 and MMP2 expression in melanoma biopsies was observed, and their concomitant expression was closely correlated with melanoma patient survival, further supporting the hypothesis that the expression of NRP1 is associated with melanoma invasion and metastasis. In conclusion, increased NRP1 expression is associated with disease progression and reduced survival in patients with melanoma, and is a promising prognostic molecular marker for this disease.
References: J Clin Oncol. 2005 Mar 1;23(7):1473-82. (PMID: 15735123)
Cell Signal. 2012 Dec;24(12):2273-82. (PMID: 22906492)
Oncotarget. 2012 Sep;3(9):921-39. (PMID: 22948112)
Clin Cancer Res. 2012 Nov 1;18(21):6040-8. (PMID: 22962439)
CA Cancer J Clin. 2013 Jan;63(1):11-30. (PMID: 23335087)
Cell. 2013 Feb 28;152(5):1065-76. (PMID: 23452854)
Int J Oncol. 2013 Jul;43(1):297-306. (PMID: 23685409)
Asian Pac J Trop Med. 2013 Oct;6(10):826-30. (PMID: 23870474)
J Invest Dermatol. 2000 Sep;115(3):337-44. (PMID: 10951266)
J Biol Chem. 2001 Jul 6;276(27):25520-31. (PMID: 11333271)
Cancer Res. 2001 Aug 1;61(15):5736-40. (PMID: 11479209)
Blood. 2002 Dec 15;100(13):4622-8. (PMID: 12453880)
Br J Cancer. 2003 Oct 6;89(7):1270-5. (PMID: 14520459)
Am J Pathol. 2004 Jun;164(6):2139-51. (PMID: 15161648)
Angiogenesis. 2003;6(4):295-301. (PMID: 15166498)
Cell. 1998 Mar 20;92(6):735-45. (PMID: 9529250)
Cancer Metastasis Rev. 2006 Mar;25(1):9-34. (PMID: 16680569)
N Engl J Med. 2006 Jul 6;355(1):51-65. (PMID: 16822996)
Mol Carcinog. 2006 Nov;45(11):871-80. (PMID: 16847823)
Cancer Cell. 2007 Jan;11(1):53-67. (PMID: 17222790)
Clin Cancer Res. 2007 Aug 15;13(16):4759-68. (PMID: 17699853)
J Am Acad Dermatol. 2007 Oct;57(4):555-72; quiz 573-6. (PMID: 17870429)
Hum Pathol. 2008 Mar;39(3):377-85. (PMID: 18187184)
Cancer Res. 2008 Nov 1;68(21):8667-72. (PMID: 18974107)
Am J Health Syst Pharm. 2008 Dec 15;65(24 Suppl 9):S3-8. (PMID: 19052264)
Clin Cancer Res. 2009 Mar 15;15(6):1860-4. (PMID: 19240167)
Clin Cancer Res. 2009 Oct 15;15(20):6404-11. (PMID: 19808872)
J Clin Oncol. 2009 Dec 20;27(36):6199-206. (PMID: 19917835)
Oncol Rep. 2010 Feb;23(2):537-44. (PMID: 20043119)
Br J Cancer. 2010 Feb 2;102(3):541-52. (PMID: 20087344)
Curr Med Chem. 2011;18(23):3563-75. (PMID: 21756227)
Nature. 2011 Oct 20;478(7369):399-403. (PMID: 22012397)
Cell Oncol (Dordr). 2012 Jun;35(3):207-16. (PMID: 22669775)
Am J Pathol. 2012 Aug;181(2):693-705. (PMID: 22659470)
معلومات مُعتمدة: CCI‑117958 Canada Canadian Institutes of Health Research
المشرفين على المادة: 0 (Biomarkers, Tumor)
144713-63-3 (Neuropilin-1)
EC 3.4.24.24 (Matrix Metalloproteinase 2)
تواريخ الأحداث: Date Created: 20150509 Date Completed: 20160310 Latest Revision: 20181113
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC4464456
DOI: 10.3892/mmr.2015.3752
PMID: 25954957
قاعدة البيانات: MEDLINE
الوصف
تدمد:1791-3004
DOI:10.3892/mmr.2015.3752